Covid-PSMID
Click the up/down buttons found in the upper left or bottom left corner of the document to navigate. This document has 42 pages.
Return to Philippine COVID-19 Living Recommendations.
Covid-PSMID
Click the up/down buttons found in the upper left or bottom left corner of the document to navigate. This document has 13 pages.
Return to Philippine COVID-19 Living Recommendations.
Covid-PSMID
Click the up/down buttons found in the upper left or bottom left corner of the document to navigate. This document has 22 pages.
Return to Philippine COVID-19 Living Recommendations.
Covid-PSMID
Click the up/down buttons found in the upper left or bottom left corner of the document to navigate. This document has 6 pages.
Return to Philippine COVID-19 Living Recommendations.
Covid-PSMID
Click the up/down buttons found in the upper left or bottom left corner of the document to navigate. This document has 16 pages.
Return to Philippine COVID-19 Living Recommendations.
Covid-PSMID
Click the up/down buttons found in the upper left or bottom left corner of the document to navigate. This document has 6 pages.
Return to Philippine COVID-19 Living Recommendations.
Clinical Practice Guidelines
Community acquired pneumonia is a significant cause of morbidity and mortality among adults, still remaining as the leading cause of death from an infectious disease. Since the last publication of Philippine Clinical Practice Guidelines on the Diagnosis, Empiric Management, and Prevention of Community-acquired Pneumonia in Immunocompetent Adults in 2016, several important changes have emerged, including increasing rates of multi-drug resistant organisms (MDROs) among respiratory pathogens, the development of new antimicrobial agents meant to address these MDROs, the misuse and overuse of antimicrobial agents. It is for these reasons that an update on the management of CAP is needed.
The following are the guideline’s objectives:
This guideline is intended for use of medical specialists in infectious diseases, pulmonology, family medicine, as well as general practitioners, clinical practitioners, nurses and other health care providers as well as administrators, and policy makers. It can be used in the hospital and community setting—from primary to tertiary level in both private and government clinics or hospitals.
The guideline shall cover all adults, including the elderly, presenting with CAP in the outpatient and in-patient setting except:
There are 17 priority questions identified and 30 corresponding recommendations developed by a group of experts composed of an Oversight Committee, a Guideline Writing Panel and a Technical Review Committee (Table 1). Based on the best available evidences, the quality and strength of evidence was rated using the Grading of Recommendations, Assessment, Development and evaluation (GRADE) approach. Draft recommendations were finalized after these were presented to and voted on by the members of the Consensus Panel.
STEERING COMMITTEE
TECHNICAL WORKING GROUP
Committee on Diagnosis
Members
Committee on Management
Members
Committee on Prevention
ADVISER
CONSENSUS PANEL
Covid-PSMID
Click the up/down buttons found in the upper left or bottom left corner of the document to navigate. This document has 45 pages.
Return to Philippine COVID-19 Living Recommendations.
Covid-PSMID
Click the up/down buttons found in the upper left or bottom left corner of the document to navigate. This document has 32 pages.
Return to Philippine COVID-19 Living Recommendations.
Covid-PSMID
Click the up/down buttons found in the upper left or bottom left corner of the document to navigate. This document has 16 pages.
Return to Philippine COVID-19 Living Recommendations.
The Philippine Society for Microbiology and Infectious Diseases (PSMID) Guidance on the Management of Mpox, Ver. 1 provides the basic and most updated information on management of patients confirmed with mpox.
This guidance complements the mpox recommendations of the DOH (Updated Interim Guidelines on the Prevention, Detection, and Management of MPOX, by Department of Health, August 26, 2024, Department Memorandum 2024-0306) and PHICS-PHICNA (Interim Guidelines on the Prevention and Control of Monkeypox version 1).
The antivirals, immunoglobulin and vaccines discussed below are not available locally. In our local situation, we should maximize supportive care for mpox cases.